Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CTNM

Contineum Therapeutics Inc.

May 01 • 04:00PM ET

15.45

Dollar change -0.15
Percentage change -0.96	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	43.40%	Shs Outstand	23.40M	Perf Week	-3.01%
Market Cap	388.26M	Forward P/E	-	EPS next Y	-1.63	Insider Trans	0.00%	Shs Float	14.22M	Perf Month	-
Income	-	PEG	-	EPS next Q	-1.11	Inst Own	13.08%	Short Float	3.68%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-3827.78%	Inst Trans	-	Short Ratio	3.05	Perf Half Y	-
Book/sh	-2.70	P/B	-	EPS next Y	2.68%	ROA	-	Short Interest	0.52M	Perf Year	-
Cash/sh	4.98	P/C	3.10	EPS next 5Y	-	ROE	-	52W Range	13.90 - 16.06	Perf YTD	0.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-3.80%	Beta	-
Dividend TTM	-	Quick Ratio	23.29	Sales past 5Y	0.00%	Gross Margin	-	52W Low	11.15%	ATR (14)	0.91
Dividend Ex-Date	-	Current Ratio	23.29	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	4.34% -
Employees	31	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	28.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.25	Prev Close	15.60
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	171.53K	Price	15.45
SMA20	-0.45%	SMA50	-0.45%	SMA200	-0.45%	Trades		Volume	43,388	Change	-0.96%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Initiated	Stifel	Buy	$29
Apr-30-24	Initiated	RBC Capital Mkts	Outperform	$30
Apr-30-24	Initiated	Morgan Stanley	Overweight	$25

Apr-04-24 09:02PM

Contineum Therapeutics Announces Pricing of Initial Public Offering

(GlobeNewswire)

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTNM

Contineum Therapeutics Inc.

Upgrade your FINVIZ experience